17 articles
Carboplatin and gemcitabine regimen
The carboplatin and gemcitabine regimen, or Carboplatin-Gemcitabine, is a doublet chemotherapy pairing carboplatin with gemcitabine, standard for recurrent ovarian cancer and advanced non-small-cell lung cancer.
Carboplatin and paclitaxel regimen
The carboplatin and paclitaxel regimen, abbreviated TC or Carbo-Tax, is a two-drug intravenous chemotherapy combination treating solid tumors, most prominently non-small cell lung and ovarian cancer.
Carboplatin and pemetrexed regimen
The carboplatin and pemetrexed regimen is a doublet chemotherapy combination, given on day 1 of a 21-day cycle, used mainly as first-line treatment of advanced nonsquamous non-small-cell lung cancer and malignant pleural mesothelioma.
Carboplatin and vincristine regimen
The carboplatin and vincristine regimen (CV) is a two-drug combination chemotherapy used mainly as frontline treatment for progressive or symptomatic pediatric low-grade glioma, except BRAF V600E-mutated tumors.
Cisplatin and gemcitabine regimen
The cisplatin and gemcitabine regimen (GC or GemCis) is a two-drug intravenous chemotherapy combination pairing cisplatin with gemcitabine, established as standard first-line therapy for advanced biliary tract cancer by the 2010 ABC-02 trial.
Cisplatin and pemetrexed
Cisplatin and pemetrexed is a combination chemotherapy regimen approved in the United States and European Union in 2004, used mainly as first-line treatment of mesothelioma and nonsquamous non-small-cell lung cancer.
Cisplatin-based chemotherapy
Cisplatin-based chemotherapy is cancer treatment in which the platinum drug cisplatin anchors multi-drug regimens for solid tumors, and is best known for making metastatic testicular cancer largely curable.
Cisplatin/paclitaxel regimen
The cisplatin/paclitaxel (TP) regimen is a combination chemotherapy doublet pairing cisplatin with paclitaxel, the accepted first-line treatment for persistent, recurrent, or metastatic cervical cancer, though responses are short-lived.
Cisplatin/vinorelbine regimen
The cisplatin/vinorelbine regimen is a two-drug chemotherapy combination pairing cisplatin with vinorelbine, used mainly for advanced non-small-cell lung cancer and, less often, mesothelioma.
Demplatin pegraglumer
Demplatin pegraglumer (NC-6004, Nanoplatin) is a ~30 nm polymeric micelle formulation of cisplatin in PEG-poly(glutamic acid), developed by Kataoka's group and NanoCarrier, tested with gemcitabine in phase III pancreatic cancer trials.
Gemcitabine and oxaliplatin regimen
The gemcitabine and oxaliplatin regimen, abbreviated GemOx, is a two-drug combination chemotherapy used mainly for advanced biliary tract cancer and relapsed or refractory lymphoid malignancies.
Lobaplatin
Lobaplatin (D-19466, 注射用洛铂), a third-generation platinum chemotherapy approved in China for CML, metastatic breast cancer, and small cell lung cancer; forms GG/AG intrastrand DNA cross-links; dose-limiting toxicity is thrombocytopenia without nephro-, neuro-, or ototoxicity.
Neratinib
Neratinib (Nerlynx) is an oral irreversible pan-HER tyrosine kinase inhibitor of HER1, HER2, and HER4, FDA-approved in 2017 for extended adjuvant therapy of early-stage HER2-positive breast cancer after trastuzumab and, with capecitabine, for metastatic disease; diarrhea is its main toxicity.
Oxaliplatin
Oxaliplatin, sold as Eloxatin, is a platinum-based chemotherapy drug approved in the United States in 2002 for colorectal cancer, used with 5-fluorouracil and leucovorin; its dose-limiting toxicity is peripheral neuropathy.
Picoplatin
Picoplatin (ZD0473, AMD473), a sterically hindered 2-methylpyridine cisplatin analog developed to overcome platinum resistance; tested through phase III in small cell lung cancer but discontinued after failing to show a survival advantage.
Platinum(IV) prodrug
A platinum(IV) prodrug is an inert, six-coordinate platinum(IV) complex that is reduced inside cells to release an active platinum(II) anticancer drug such as cisplatin, satraplatin being the best-known candidate.
Satraplatin
Satraplatin (JM216, BMS-182751, Orplatna) is an oral platinum(IV) prodrug chemotherapy agent developed for prostate and other cancers; it never gained FDA approval after its SPARC Phase III trial showed no overall survival benefit.